口服シムバスタチンの治療は,再発・リミート性多発性硬化症の治療に用いられる
Timothy Vollmer1, Lyndon Key, Valerie Durkalski
1Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA.
Lancet (London, England)
|May 18, 2004
まとめ
口服シムバスタチン (80 mg) は,再発性寛解性多発性硬化症患者のガドリニウム増強性病変の軽減に有意な効果を示した. この経口治療はよく耐えており,神経障害に寄与する炎症プロセスを標的とすることがあります.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 免疫学 免疫学とは
背景:
- 多発性硬化症 (MS) の治療は,しばしば注射可能であり,部分的に有効であり,高価である.
- 再発性MSには,革新的な治療戦略が必要です.
研究 の 目的:
- 口服シムバスタチン (80 mg) の有効性と耐容性を再発性寛解性多発性硬化症 (RRMS) の患者で評価する.
主な方法:
- 30人のRRMS患者を対象とした研究では,口服シムバスタチン (80 mg) の影響を評価した.
- 脳MRIスキャンのガドリニウム増強病変は,治療の4~6ヶ月前およびその間に定量化されました.
主要な成果:
- ガドリニウム強化病変の数は44% (p<0.0001) 減少した.
- 41% (p=0.0018) の損傷容量の有意な減少でした.
- 口服のシンバスタチンは,すべての参加者によってよく耐えられました.
結論:
- 口服シムバスタチンは,再発性寛解性多発性硬化症の有効な治療法として潜在性を示しています.
- シムバスタチンは,MSに関連する神経障害に関連する炎症経路を阻害することによってその効果を発揮する可能性があります.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

